Merck & Co., Inc., Rahway, N.J., USA Financial Highlights Package Second Quarter 2026 Table of Contents Table 1: GAAP P&L....................................................................................1 Table 1a: GAAP P&L – Current Year and Prior Year by Quarter.................2 Table 2a: GAAP to Non-GAAP Reconciliation 2Q26 and June YTD 26.......3 Table 2b: GAAP to Non-GAAP Reconciliation 2Q25 and June YTD 25.......4 Table 3: Sales - Current Year and Prior Year by Quarter...........................5 Table 3a: Sales – U.S. / International 2Q26.................................................6 Table 3b: Sales – U.S. / International June YTD 26.....................................7 Table 3c: Sales – Pharmaceutical Geographic Split....................................8 Table 4: Other (Income) Expense .............................................................9 -- 1 of 10 -- Sales 16,607 $ 15,806 $ 5% 32,893 $ 31,335 $ 5% Costs, Expenses and Other Cost of sales 4,395 3,557 24% 8,590 6,976 23% Selling, general and administrative 2,904 2,649 10% 5,604 5,202 8% Research and development 9,741 4,048 * 22,333 7,669 * Restructuring costs 151 560 -73% 346 629 -45% Other (income) expense, net 99 (7) * 237 (43) * (Loss) Income Before Taxes (683) 4,999 * (4,217) 10,902 * Income Tax Provision 654 571 1,363 1,388 Net (Loss) Income (1,337) 4,428 * (5,580) 9,514 * Less: Net (Loss) Income Attributable to Noncontrolling Interests (2) 1 (5) 8 Net (Loss) Income Attributable to Merck & Co., Inc., Rahway, N.J., USA (1,335) $ 4,427 $ * (5,575) $ 9,506 $ * (Loss) Earnings per Common Share Assuming Dilution (1) (0.54) $ 1.76 $ * (2.26) $ 3.77 $ * Average Shares Outstanding Assuming Dilution (1) 2,470 2,513 2,471 2,522 Tax Rate -95.9% 11.4% -32.3% 12.7% * 100% or greater MERCK & CO., INC., RAHWAY, N.J., USA CONSOLIDATED STATEMENT OF OPERATIONS - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1 (1) Because the Company recorded a net loss in both the second quarter and first six months of 2026, no potential dilutive common shares were used in the computations of loss per common share assuming dilution as the effects would have been anti-dilutive. GAAP % Change June YTD 2026 June YTD 2025 GAAP % Change 2Q26 2Q25 1 -- 2 of 10 -- Sales 16,286 $ 16,607 $ 32,893 $ 15,529 $ 15,806 $ 31,335 $ 17,276 $ 16,400 $ 65,011 $ 5% 5% Costs, Expenses and Other Cost of sales 4,195 4,395 8,590 3,419 3,557 6,976 3,855 5,551 16,382 24% 23% Selling, general and administrative 2,700 2,904 5,604 2,552 2,649 5,202 2,633 2,898 10,733 10% 8% Research and development 12,592 9,741 22,333 3,621 4,048 7,669 4,234 3,886 15,789 * * Restructuring costs 195 151 346 69 560 629 47 213 889 -73% -45% Other (income) expense, net 138 99 237 (35) (7) (43) (238) 432 151 * * (Loss) Income Before Taxes (3,534) (683) (4,217) 5,903 4,999 10,902 6,745 3,420 21,067 * * Income Tax Provision 709 654 1,363 818 571 1,388 958 458 2,804 Net (Loss) Income (4,243) (1,337) (5,580) 5,085 4,428 9,514 5,787 2,962 18,263 * * Less: Net (Loss) Income Attributable to Noncontrolling Interests (3) (2) (5) 6 1 8 2 (1) 9 Net (Loss) Income Attributable to Merck & Co., Inc., Rahway, N.J., USA (4,240) $ (1,335) $ (5,575) $ 5,079 $ 4,427 $ 9,506 $ 5,785 $ 2,963 $ 18,254 $ * * (Loss) Earnings per Common Share Assuming Dilution (1) (1.72) $ (0.54) $ (2.26) $ 2.01 $ 1.76 $ 3.77 $ 2.32 $ 1.19 $ 7.28 $ * * Average Shares Outstanding Assuming Dilution (1) 2,472 2,470 2,471 2,531 2,513 2,522 2,498 2,488 2,507 Tax Rate -20.1% -95.9% -32.3% 13.9% 11.4% 12.7% 14.2% 13.4% 13.3% * 100% or greater Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (1) Because the Company recorded a net loss in both the second quarter and first six months of 2026, no potential dilutive common shares were used in the computations of loss per common share assuming dilution as the effects would have been anti-dilutive. % Change 4Q 2Q Full Year Full Year 2026 2Q 1Q 1Q 2Q 3Q 2025 June YTD June YTD MERCK & CO., INC., RAHWAY, N.J., USA CONSOLIDATED STATEMENT OF OPERATIONS - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a 2 -- 3 of 10 -- Second Quarter Cost of sales 4,395 $ 1,067 184 1,251 3,144 $ Selling, general and administrative 2,904 17 17 2,887 Research and development 9,741 6 (1) 5 9,736 Restructuring costs 151 151 151 – Other (income) expense, net 99 (191) (191) 290 Loss Before Taxes (683) (1,090) (334) 191 (1,233) 550 Income Tax Provision (Benefit) 654 (219) (3) (50) (3) 41 (3) (228) 882 Net Loss (1,337) (871) (284) 150 (1,005) (332) Net Loss Attributable to Merck & Co., Inc., Rahway, N.J., USA (1,335) (871) (284) 150 (1,005) (330) Loss per Common Share Assuming Dilution (4) (0.54) $ (0.35) (0.12) 0.06 (0.41) (0.13) $ Tax Rate -95.9% 160.3% June YTD Cost of sales 8,590 $ 2,081 421 2,502 6,088 $ Selling, general and administrative 5,604 49 49 5,555 Research and development 22,333 6 33 39 22,294 Restructuring costs 346 346 346 – Other (income) expense, net 237 (371) (371) 608 Loss Before Taxes (4,217) (2,136) (800) 371 (2,565) (1,652) Income Tax Provision (Benefit) 1,363 (421) (3) (135) (3) 80 (3) (476) 1,839 Net Loss (5,580) (1,715) (665) 291 (2,089) (3,491) Net Loss Attributable to Merck & Co., Inc., Rahway, N.J., USA (5,575) (1,715) (665) 291 (2,089) (3,486) Loss per Common Share Assuming Dilution (4) (2.26) $ (0.70) (0.27) 0.12 (0.85) (1.41) $ Tax Rate -32.3% -111.3% Only the line items that are affected by non-GAAP adjustments are shown. (4) Because the Company recorded a net loss in both the second quarter and first six months of 2026, no potential dilutive common shares were used in the computations of loss per common share assuming dilution as the effects would have been anti-dilutive. The Company is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non-GAAP information enhances investors’ understanding of the Company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amounts included in cost of sales reflect expenses for the amortization of intangible assets, as well as the recognition of fair value step-up of inventories related to the 2025 Verona Pharma plc acquisition. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures. (2) Amounts primarily include employee separation costs, accelerated depreciation and asset impairment charges associated with facilities to be closed or divested, as well as contractual termination costs, associated with activities under the Company's formal restructuring programs. (3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. MERCK & CO., INC., RAHWAY, N.J., USA THREE AND SIX MONTHS ENDED JUNE 30, 2026 GAAP TO NON-GAAP RECONCILIATION (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 2a GAAP Acquisition- and Divestiture- Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities Adjustment Subtotal Non-GAAP 3 -- 4 of 10 -- Second Quarter Cost of sales 3,557 $ 576 165 741 2,816 $ Selling, general and administrative 2,649 15 1 16 2,633 Research and development 4,048 3 53 56 3,992 Restructuring costs 560 560 560 – Other (income) expense, net (7) (61) (61) 54 Income Before Taxes 4,999 (594) (779) 61 (1,312) 6,311 Income Tax Provision (Benefit) 571 (102) (3) (139) (3) 14 (3) (146) (4) (373) 944 Net Income 4,428 (492) (640) 47 146 (939) 5,367 Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA 4,427 (492) (640) 47 146 (939) 5,366 Earnings per Common Share Assuming Dilution 1.76 $ (0.20) (0.25) 0.02 0.06 (0.37) 2.13 $ Tax Rate 11.4% 15.0% June YTD Cost of sales 6,976 $ 1,196 201 1,397 5,579 $ Selling, general and administrative 5,202 38 1 39 5,163 Research and development 7,669 10 53 63 7,606 Restructuring costs 629 629 629 – Other (income) expense, net (43) (3) (168) (171) 128 Income Before Taxes 10,902 (1,241) (884) 168 (1,957) 12,859 Income Tax Provision (Benefit) 1,388 (219) (3) (157) (3) 36 (3) (146) (4) (486) 1,874 Net Income 9,514 (1,022) (727) 132 146 (1,471) 10,985 Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA 9,506 (1,022) (727) 132 146 (1,471) 10,977 Earnings per Common Share Assuming Dilution 3.77 $ (0.40) (0.29) 0.05 0.06 (0.58) 4.35 $ Tax Rate 12.7% 14.6% Only the line items that are affected by non-GAAP adjustments are shown. (3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. (4) Represents tax benefits primarily resulting from favorable audit reserve adjustments. Non-GAAP The Company is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non-GAAP information enhances investors’ understanding of the Company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amounts included in cost of sales reflect expenses for the amortization of intangible assets and intangible asset impairment charges, partially offset by a decrease in the estimated fair value measurement of liabilities for contingent consideration. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures. Amounts included in research and development expenses reflect the amortization of intangible assets. (2) Amounts primarily include employee separation costs, accelerated depreciation and asset impairments associated with facilities to be closed or divested related to activities under the Company's formal restructuring programs. GAAP Acquisition- and Divestiture-Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities Certain Other Items Adjustment Subtotal MERCK & CO., INC., RAHWAY, N.J., USA THREE AND SIX MONTHS ENDED JUNE 30, 2025 GAAP TO NON-GAAP RECONCILIATION (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 2b 4 -- 5 of 10 -- MERCK & CO., INC., RAHWAY, N.J., USA FRANCHISE / KEY PRODUCT SALES (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3 2026 2025 2Q June YTD 1Q 2Q June YTD 1Q 2Q June YTD 3Q 4Q Full Year Nom % Ex-Exch % Nom % Ex-Exch % TOTAL SALES (1) $16,286 $16,607 $32,893 $15,529 $15,806 $31,335 $17,276 $16,400 $65,011 5 4 5 3 PHARMACEUTICAL 14,349 14,760 29,109 13,638 14,050 27,688 15,611 14,843 58,142 5 4 5 3 Oncology Keytruda 7,906 7,904 15,810 7,205 7,956 15,161 8,142 8,337 31,641 -1 -2 4 2 Keytruda Qlex 128 463 590 5 35 40 - - - - Alliance Revenue – Lynparza (2) 341 365 706 312 370 682 379 389 1,450 -1 -2 4 2 Alliance Revenue – Lenvima (2) 256 283 539 258 265 523 258 272 1,053 7 6 3 2 Welireg 199 271 470 137 162 300 196 220 716 67 67 57 56 Alliance Revenue – Reblozyl (3) 148 122 270 119 107 226 136 164 525 15 15 20 20 Vaccines (4) Gardasil/Gardasil 9 1,069 1,169 2,238 1,327 1,126 2,453 1,749 1,031 5,233 4 3 -9 -10 ProQuad/M-M-R II/Varivax 538 592 1,130 539 609 1,148 684 619 2,451 -3 -3 -2 -3 Vaxneuvance 202 148 350 230 229 459 226 140 825 -35 -36 -24 -26 RotaTeq 206 134 340 228 121 349 204 119 673 10 9 -3 -4 Capvaxive 142 184 325 107 129 236 244 279 759 42 40 38 36 Enflonsia 1 2 3 79 21 100 - - - - Cardiometabolic & Respiratory Winrevair 525 588 1,114 280 336 615 360 467 1,443 75 75 81 81 Ohtuvayre 131 204 335 178 178 - - - - Alliance Revenue - Adempas/Verquvo (5 109 126 235 106 123 229 112 129 470 3 3 3 3 Adempas (6) 78 78 156 68 80 147 82 83 312 -2 -4 6 1 Infectious Diseases Bridion 472 497 969 441 461 902 439 499 1,841 8 8 7 7 Prevymis 272 295 568 208 228 436 266 275 978 29 28 30 27 Delstrigo 75 101 176 67 83 150 77 79 306 21 17 17 10 Zerbaxa 82 77 159 70 74 145 81 87 312 4 2 10 8 Isentress/Isentress HD 59 60 119 90 86 176 82 67 325 -30 -31 -32 -33 Dificid 34 22 56 83 96 179 43 25 247 -77 -77 -69 -69 Lagevrio 28 5 32 102 83 185 138 57 380 -95 -95 -82 -83 Diabetes Januvia 367 258 625 549 372 921 382 302 1,604 -31 -30 -32 -32 Janumet 207 171 378 247 251 498 243 199 940 -32 -33 -24 -25 Other Pharmaceutical (7) 774 641 1,416 865 703 1,568 1,004 770 3,340 -9 -9 -10 -11 ANIMAL HEALTH 1,791 1,775 3,566 1,588 1,646 3,234 1,615 1,505 6,354 8 5 10 6 Livestock 1,064 1,041 2,105 924 961 1,885 1,023 987 3,896 8 6 12 7 Companion Animal 727 734 1,461 664 685 1,349 592 518 2,458 7 5 8 4 Other Revenues (8) 146 72 218 303 110 413 50 52 515 -35 -34 -47 -6 Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (7) Includes Pharmaceutical products not individually shown above. Also reflects total alliance revenue for Koselugo of $161 million and $10 million in the first and second quarter of 2026, respectively, and $44 million and $43 million in the first and second quarter of 2025, respectively. (8) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of milestone payments for out-licensed products were $132 million and $0 million in the first and second quarter of 2026, respectively, and $95 million and $5 million in the first and second quarter of 2025, respectively. (1) Only select products are shown. (2) Alliance Revenue represents the Company's share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties. (4) Total Vaccines sales were $2,314 million and $2,361 million in the first and second quarter of 2026, respectively, and $2,607 million and $2,370 million in the first and second quarter of 2025, respectively. (5) Alliance Revenue represents the Company's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. (6) Net product sales in the Company's marketing territories. 5 -- 6 of 10 -- Global U.S. International 2Q 2026 2Q 2025 % Change 2Q 2026 2Q 2025 % Change 2Q 2026 2Q 2025 % Change TOTAL SALES (1) $16,607 $15,806 5 $9,367 $8,836 6 $7,240 $6,969 4 PHARMACEUTICAL 14,760 14,050 5 8,827 8,328 6 5,933 5,722 4 Oncology Keytruda 7,904 7,956 -1 4,611 4,749 -3 3,293 3,207 3 Keytruda Qlex 463 - 395 - 68 - Alliance Revenue – Lynparza (2) 365 370 -1 167 174 -4 198 195 2 Alliance Revenue – Lenvima (2) 283 265 7 194 183 6 90 83 8 Welireg 271 162 67 214 138 55 57 24 133 Alliance Revenue – Reblozyl (3) 122 107 15 98 88 11 25 19 31 Vaccines (4) Gardasil/Gardasil 9 1,169 1,126 4 542 545 -1 626 581 8 ProQuad/M-M-R II/Varivax 592 609 -3 438 481 -9 154 128 20 Capvaxive 184 129 42 138 129 7 45 - Vaxneuvance 148 229 -35 69 136 -50 80 93 -14 RotaTeq 134 121 10 84 60 39 50 61 -18 Enflonsia 2 - 2 - Cardiometabolic & Respiratory Winrevair 588 336 75 522 323 61 66 12 * Ohtuvayre 204 - 204 - Alliance Revenue - Adempas/Verquvo (5) 126 123 3 112 108 4 14 15 -1 Adempas (6) 78 80 -2 78 80 -2 Infectious Diseases Bridion 497 461 8 460 411 12 37 50 -25 Prevymis 295 228 29 147 115 28 148 113 31 Delstrigo 101 83 21 13 14 -7 88 70 27 Zerbaxa 77 74 4 44 45 -3 34 29 14 Isentress/Isentress HD 60 86 -30 36 48 -26 24 38 -36 Dificid 22 96 -77 11 83 -87 12 13 -11 Lagevrio 5 83 -95 1 30 -96 3 52 -94 Diabetes Januvia 258 372 -31 149 216 -31 109 155 -30 Janumet 171 251 -32 28 68 -59 143 184 -22 Other Pharmaceutical (7) 641 703 -9 150 184 -18 489 520 -6 ANIMAL HEALTH 1,775 1,646 8 535 499 7 1,240 1,147 8 Livestock 1,041 961 8 202 190 6 838 771 9 Companion Animal 734 685 7 333 309 8 402 376 7 Other Revenues (8) 72 110 -35 5 9 -44 67 100 -33 *200% or greater Table 3a MERCK & CO., INC., RAHWAY, N.J., USA FRANCHISE / KEY PRODUCT SALES SECOND QUARTER 2026 (AMOUNTS IN MILLIONS) (UNAUDITED) (6) Net product sales in the Company's marketing territories. (7) Includes Pharmaceutical products not individually shown above. Also reflects total alliance revenue for Koselugo of $10 million and $43 million on a global basis in the second quarter of 2026 and 2025, respectively. (8) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue- hedging activities. Other Revenues related to the receipt of milestone payments for out-licensed products were $0 million and $5 million on a global basis in the second quarter of 2026 and 2025, respectively. Sum of U.S. plus international may not equal global due to rounding. (1) Only select products are shown. (2) Alliance Revenue represents the Company's share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties. (4) Total Vaccines sales were $2,361 million and $2,370 million on a global basis in the second quarter of 2026 and 2025, respectively. (5) Alliance Revenue represents the Company's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. 6 -- 7 of 10 -- Global U.S. International June YTD 2026 June YTD 2025 % Change June YTD 2026 June YTD 2025 % Change June YTD 2026 June YTD 2025 % Change TOTAL SALES (1) $32,893 $31,335 5 $18,532 $17,359 7 $14,361 $13,977 3 PHARMACEUTICAL 29,109 27,688 5 17,338 16,254 7 11,771 11,434 3 Oncology Keytruda 15,810 15,161 4 9,210 9,057 2 6,600 6,104 8 Keytruda Qlex 590 - 501 - 89 - Alliance Revenue – Lynparza (2) 706 682 4 315 319 -1 391 363 8 Alliance Revenue – Lenvima (2) 539 523 3 369 368 0 170 155 9 Welireg 470 300 57 366 261 40 103 39 166 Alliance Revenue – Reblozyl (3) 270 226 20 226 189 20 45 37 21 Vaccines (4) Gardasil/Gardasil 9 2,238 2,453 -9 1,027 1,082 -5 1,211 1,371 -12 ProQuad/M-M-R II/Varivax 1,130 1,148 -2 847 903 -6 283 245 16 Capvaxive 325 236 38 256 235 9 69 1 * Vaxneuvance 350 459 -24 192 275 -30 158 184 -14 RotaTeq 340 349 -3 249 225 11 91 125 -27 Enflonsia 3 - -1 - 4 - Cardiometabolic & Respiratory Winrevair 1,114 615 81 999 591 69 114 24 * Ohtuvayre 335 - 335 - Alliance Revenue - Adempas/Verquvo (5) 235 229 3 221 205 8 14 23 -40 Adempas (6) 156 147 6 156 147 6 Infectious Diseases Bridion 969 902 7 887 789 12 82 113 -27 Prevymis 568 436 30 282 217 30 285 219 30 Delstrigo 176 150 17 23 29 -21 153 121 26 Zerbaxa 159 145 10 95 87 9 64 57 12 Isentress/Isentress HD 119 176 -32 71 99 -29 49 77 -37 Dificid 56 179 -69 35 155 -77 21 24 -10 Lagevrio 32 185 -82 18 66 -73 15 119 -87 Diabetes Januvia 625 921 -32 401 561 -29 224 360 -38 Janumet 378 498 -24 96 133 -28 283 366 -23 Other Pharmaceutical (7) 1,416 1,568 -10 318 408 -22 1,097 1,160 -5 ANIMAL HEALTH 3,566 3,234 10 1,054 1,001 5 2,512 2,233 12 Livestock 2,105 1,885 12 414 384 8 1,691 1,501 13 Companion Animal 1,461 1,349 8 640 617 4 821 732 12 Other Revenues (8) 218 413 -47 140 104 35 78 310 -75 *200% or greater Table 3b MERCK & CO., INC., RAHWAY, N.J., USA FRANCHISE / KEY PRODUCT SALES JUNE YEAR-TO-DATE 2026 (AMOUNTS IN MILLIONS) (UNAUDITED) (6) Net product sales in the Company's marketing territories. (7) Includes Pharmaceutical products not individually shown above. Also reflects total alliance revenue for Koselugo of $171 million and $87 million on a global basis for June YTD 2026 and 2025, respectively. (8) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of milestone payments for out-licensed products were $132 million and $100 million on a global basis for June YTD 2026 and 2025, respectively. Sum of U.S. plus international may not equal global due to rounding. (1) Only select products are shown. (2) Alliance Revenue represents the Company's share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties. (4) Total Vaccines sales were $4,675 million and $4,977 million on a global basis for June YTD 2026 and 2025, respectively. (5) Alliance Revenue represents the Company's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. 7 -- 8 of 10 -- MERCK & CO., INC., RAHWAY, N.J., USA PHARMACEUTICAL GEOGRAPHIC SALES (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3c 2026 2025 % Change 1Q 2Q June YTD 1Q 2Q June YTD 3Q 4Q Full Year 2Q June YTD TOTAL PHARMACEUTICAL $14,349 $14,760 $29,109 $13,638 $14,050 $27,688 $15,611 $14,843 $58,142 5 5 United States 8,512 8,827 17,338 7,927 8,328 16,254 9,493 8,662 34,409 6 7 % Pharmaceutical Sales 59.3% 59.8% 59.6% 58.1% 59.3% 58.7% 60.8% 58.4% 59.2% Europe (1) 2,725 2,801 5,525 2,384 2,551 4,935 2,675 2,839 10,449 10 12 % Pharmaceutical Sales 19.0% 19.0% 19.0% 17.5% 18.2% 17.8% 17.1% 19.1% 18.0% Latin America 624 636 1,260 589 654 1,243 691 644 2,578 -3 1 % Pharmaceutical Sales 4.3% 4.3% 4.3% 4.3% 4.7% 4.5% 4.4% 4.3% 4.4% Asia Pacific (other than China and Japan) 569 636 1,205 535 609 1,144 593 586 2,323 5 5 % Pharmaceutical Sales 4.0% 4.3% 4.1% 3.9% 4.3% 4.1% 3.8% 4.0% 4.0% Japan 535 558 1,093 651 604 1,255 693 684 2,632 -8 -13 % Pharmaceutical Sales 3.7% 3.8% 3.8% 4.8% 4.3% 4.5% 4.4% 4.6% 4.5% Eastern Europe/Middle East/Africa 413 408 821 435 451 886 365 348 1,598 -10 -7 % Pharmaceutical Sales 2.9% 2.8% 2.8% 3.2% 3.2% 3.2% 2.3% 2.3% 2.7% China 353 368 721 668 407 1,075 377 364 1,816 -9 -33 % Pharmaceutical Sales 2.5% 2.5% 2.5% 4.9% 2.9% 3.9% 2.4% 2.5% 3.1% Canada 137 154 291 125 135 261 134 153 547 14 12 % Pharmaceutical Sales 1.0% 1.0% 1.0% 0.9% 1.0% 0.9% 0.9% 1.0% 0.9% Other 481 372 855 324 311 635 590 563 1,790 20 35 % Pharmaceutical Sales 3.3% 2.5% 2.9% 2.4% 2.1% 2.4% 3.9% 3.8% 3.2% Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom. 8 -- 9 of 10 -- OTHER (INCOME) EXPENSE, NET 2Q26 2Q25 June YTD 2026 June YTD 2025 Interest income (35) $ (69) $ (70) $ (178) $ Interest expense 525 305 1,004 618 Exchange losses 37 78 75 167 Income from investments in equity securities, net (1) (242) (100) (411) (189) Net periodic defined benefit plan (credit) cost other than service cost (127) (152) (262) (300) Other, net (59) (69) (99) (161) Total 99 $ (7) $ 237 $ (43) $ (1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. MERCK & CO., INC., RAHWAY, N.J., USA OTHER (INCOME) EXPENSE, NET - GAAP (AMOUNTS IN MILLIONS) (UNAUDITED) Table 4 9 -- 10 of 10 --